Professor Christopher Marshall
Prosiectau fel Prif Ymchwiliwr
- 3-D printed sources for high-resolution molecular imaging (01.01.2014 - 31.12.2014)
- Advanced FDG PET-CT target volume delineation in intensity modulated radiotherapy planning for head and neck cancers (01.11.2014 - 31.10.2015)
- Assessment of the dopaminergic system in vivo using 18F fallypride PET (05.01.2015 - 15.01.2016)
- Assess the safety and efficacy of intermittent bilateral intraputamenal clial cell line-derived neutrophic factor (GDNF) infusions administered via convection enhanced delivery (CED) in subjects with Parkinson's Disease (19.06.2014 - 30.06.2016)
- Development of Functional neuroimaging pathway for patients with suspected dementia in the ABUHB area enabling access to FDGPET and Amyloid PET scans were appropriate. (01.04.2019 - 31.03.2020)
Prosiectau fel Cyd-Ymchwiliwr
- 18F-Gemcitabine as diagnostic tool in personalised chemotherapy (01.06.2017 - 31.10.2018)
- IDEA - Integrated DEmentiA research environment (01.04.2015 - 31.03.2016)
- Improving outcomes for patients with pituitary disease: advancing therapeutics and diagnostics using electronic health records and molecular imaging (01.12.2021 - 31.07.2024)
- Longitudinal monitoring of T lymphocyte migration in vivo (01.08.2015 - 31.08.2018)
- Multi-Modal theranostics (MMTs) - towards personalized cancer therapies (01.07.2014 - 30.04.2016)